JP2018527386A - ニコチン製剤、ならびにこれを作製および使用する方法 - Google Patents

ニコチン製剤、ならびにこれを作製および使用する方法 Download PDF

Info

Publication number
JP2018527386A
JP2018527386A JP2018514457A JP2018514457A JP2018527386A JP 2018527386 A JP2018527386 A JP 2018527386A JP 2018514457 A JP2018514457 A JP 2018514457A JP 2018514457 A JP2018514457 A JP 2018514457A JP 2018527386 A JP2018527386 A JP 2018527386A
Authority
JP
Japan
Prior art keywords
nicotine
formulation
particles
less
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018514457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527386A5 (enExample
Inventor
アレックス シュテンツラー
アレックス シュテンツラー
ノエ ザメル
ノエ ザメル
アーサー スルツキー
アーサー スルツキー
スティーヴン エリス
スティーヴン エリス
スティーヴ ハン
スティーヴ ハン
Original Assignee
フィリップ・モーリス・プロダクツ・ソシエテ・アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィリップ・モーリス・プロダクツ・ソシエテ・アノニム filed Critical フィリップ・モーリス・プロダクツ・ソシエテ・アノニム
Publication of JP2018527386A publication Critical patent/JP2018527386A/ja
Publication of JP2018527386A5 publication Critical patent/JP2018527386A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2018514457A 2015-09-16 2016-09-15 ニコチン製剤、ならびにこれを作製および使用する方法 Pending JP2018527386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/856,129 US11224594B2 (en) 2015-09-16 2015-09-16 Nicotine formulations and methods of making and using the same
US14/856,129 2015-09-16
PCT/US2016/051961 WO2017048972A1 (en) 2015-09-16 2016-09-15 Nicotine formulations and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2018527386A true JP2018527386A (ja) 2018-09-20
JP2018527386A5 JP2018527386A5 (enExample) 2019-10-17

Family

ID=58257033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018514457A Pending JP2018527386A (ja) 2015-09-16 2016-09-15 ニコチン製剤、ならびにこれを作製および使用する方法

Country Status (10)

Country Link
US (1) US11224594B2 (enExample)
EP (1) EP3349755B1 (enExample)
JP (1) JP2018527386A (enExample)
KR (1) KR102696600B1 (enExample)
CN (1) CN106539793B (enExample)
CA (1) CA2998950A1 (enExample)
IL (1) IL258139A (enExample)
MX (1) MX2018003271A (enExample)
RU (1) RU2722446C2 (enExample)
WO (1) WO2017048972A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524648A (ja) * 2016-06-30 2019-09-05 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子および組成物
JP2026509960A (ja) * 2022-10-27 2026-03-26 ケーティー アンド ジー コーポレイション 吸入用低容量ニコチン乾燥粉末組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
WO2019003118A1 (en) * 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
CN113208148B (zh) * 2021-05-12 2022-11-04 云南中烟工业有限责任公司 一种协同释放尼古丁和致香成分的超分子凝胶
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017679A1 (en) * 1993-02-08 1994-08-18 Advanced Therapeutic Products, Inc. Dry powder delivery system
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
JP2002506017A (ja) * 1998-03-11 2002-02-26 スラトスキー．アート ニコチン吸入器
JP2003519175A (ja) * 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2003530425A (ja) * 2000-04-17 2003-10-14 ヴェクトゥラ リミテッド 吸入器で使用するための製剤におけるまたはそれに関する改良
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US20090068276A1 (en) * 2007-05-22 2009-03-12 Vectura Group Plc Pharmaceutical compositions
JP2011510963A (ja) * 2008-02-01 2011-04-07 ベクトゥラ・リミテッド 懸濁製剤
JP2014522880A (ja) * 2011-08-08 2014-09-08 プロソニックス リミテッド 製剤組成物
WO2015123219A1 (en) * 2014-02-11 2015-08-20 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146954C (en) 1995-04-12 2008-06-17 Arthur Slutsky Breath activated nicotine inhalers
CA2265198C (en) 1998-03-11 2009-01-27 Zamel, Noe Method of producing a nicotine medicament and a medicament made by the method
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20060178394A1 (en) 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
CA2648291A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
EP2086317A4 (en) 2006-12-01 2010-03-03 Aradigm Corp NICOTINE FORMULATIONS, KITS AND SYSTEMS AND METHOD FOR THEIR USE
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
KR20100069333A (ko) 2008-12-16 2010-06-24 홍성엽 흡입식 경구 투여 금연 보조제
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
GB201215273D0 (en) 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
PL2925395T3 (pl) 2012-11-28 2019-08-30 Fontem Holdings 1 B.V. Urządzenie wytwarzające aerozol kondensacyjny z ciekłej formulacji
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
KR20190075168A (ko) 2014-04-08 2019-06-28 필립모리스 프로덕츠 에스.에이. 니코틴 제형 및 이의 제조방법
CA2943459C (en) 2014-04-28 2023-05-02 Philip Morris Products S.A. Nicotine powder inhaler
CN106170313B (zh) 2014-04-28 2020-11-10 菲利普莫里斯生产公司 带香味尼古丁粉末吸入器
EP4603486A3 (en) * 2014-05-27 2025-10-15 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US9968125B2 (en) 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017679A1 (en) * 1993-02-08 1994-08-18 Advanced Therapeutic Products, Inc. Dry powder delivery system
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
JP2002506017A (ja) * 1998-03-11 2002-02-26 スラトスキー．アート ニコチン吸入器
JP2003519175A (ja) * 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2003530425A (ja) * 2000-04-17 2003-10-14 ヴェクトゥラ リミテッド 吸入器で使用するための製剤におけるまたはそれに関する改良
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US20090068276A1 (en) * 2007-05-22 2009-03-12 Vectura Group Plc Pharmaceutical compositions
JP2011510963A (ja) * 2008-02-01 2011-04-07 ベクトゥラ・リミテッド 懸濁製剤
JP2014522880A (ja) * 2011-08-08 2014-09-08 プロソニックス リミテッド 製剤組成物
WO2015123219A1 (en) * 2014-02-11 2015-08-20 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524648A (ja) * 2016-06-30 2019-09-05 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子および組成物
JP2026509960A (ja) * 2022-10-27 2026-03-26 ケーティー アンド ジー コーポレイション 吸入用低容量ニコチン乾燥粉末組成物

Also Published As

Publication number Publication date
RU2018113272A3 (enExample) 2019-10-16
IL258139A (en) 2018-05-31
EP3349755A4 (en) 2019-04-24
CN106539793B (zh) 2020-06-30
RU2018113272A (ru) 2019-10-16
US11224594B2 (en) 2022-01-18
US20170071929A1 (en) 2017-03-16
EP3349755C0 (en) 2025-02-19
CA2998950A1 (en) 2017-03-23
EP3349755A1 (en) 2018-07-25
MX2018003271A (es) 2018-05-16
KR20180055819A (ko) 2018-05-25
KR102696600B1 (ko) 2024-08-21
RU2722446C2 (ru) 2020-06-01
CN106539793A (zh) 2017-03-29
EP3349755B1 (en) 2025-02-19
WO2017048972A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
JP7575183B2 (ja) 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
US11707432B2 (en) System and method for controlling the harshness of nicotine-based dry powder formulations
KR102696600B1 (ko) 니코틴 제형, 및 이의 이용 및 제조방법
US10660883B2 (en) Inhalable nicotine formulations, and methods of making and using thereof
JP7680823B2 (ja) 吸入可能なニコチン製剤、およびその作製および使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111